Founded in Paris in 1920, Gide is a leading international law firm with 12 offices spread throughout the world.
Gide is physically present in six regions of the world, with 11 offices, enabling it to act on cases globally.
Gide has advised Cure51, a techbio company seeking to unlock the biological mechanisms responsible for exceptional survivors among cancer patients, on raising 15 million euros from Sofinnova Partners.
Other investors included: Hitachi Ventures GmbH, Life Extension Ventures, Xavier Niel, and Olivier Pomel, CEO, and co-founder of Datadog.
The funding received will enable Cure51 to build a unique cohort, exploring the molecular processes by which certain cancer patients survive for very extended periods of time despite having highly aggressive forms of the disease.
Gide's team comprised partner Paul Jourdan-Nayrac, Bastien Duclos on the corporate aspects ; partner Julien Guinot Delery and counsel Aurélie Pacaud on the IT/Data aspects.
The investors were advised by McDermott Will & Emery with Anthony Paronneau et Lucie Martin.
